Cover Image
市場調查報告書

Tacere Therapeutics, Inc.的產品平台分析

Tacere Therapeutics, Inc. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 310651
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Tacere Therapeutics, Inc.的產品平台分析 Tacere Therapeutics, Inc. - Product Pipeline Review - 2014
出版日期: 2014年07月31日 內容資訊: 英文 27 Pages
簡介

Tacere Therapeutics, Inc.是總公司位於美國的生物科技企業,提供C型肝炎等感染疾病的治療藥開發,及利用RNAi法的治療藥開發等相關服務。

本報告提供Tacere Therapeutics, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Tacere Therapeutics, Inc.的基本資料

  • Tacere Therapeutics, Inc.概要
  • 主要資訊
  • 企業資料

Tacere Therapeutics, Inc.:R&D概要

  • 主要的治療範圍

Tacere Therapeutics, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Tacere Therapeutics, Inc.:開發中產品概況

  • 臨床階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Tacere Therapeutics, Inc.:藥物簡介

  • TT-034
  • TT-033
  • TT-231
  • TT-211

Tacere Therapeutics, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Tacere Therapeutics, Inc.:最新的開發平台資訊

Tacere Therapeutics, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06159CDB

Summary

Global Markets Direct's, 'Tacere Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Tacere Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Tacere Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Tacere Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Tacere Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Tacere Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Tacere Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Tacere Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Tacere Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Tacere Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Tacere Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Tacere Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Tacere Therapeutics, Inc. Snapshot
    • Tacere Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Tacere Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Tacere Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Tacere Therapeutics, Inc. - Pipeline Products Glance
    • Tacere Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Tacere Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Tacere Therapeutics, Inc. - Drug Profiles
    • TT-034
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-033
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-231
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TT-211
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Tacere Therapeutics, Inc. - Pipeline Analysis
    • Tacere Therapeutics, Inc. - Pipeline Products by Target
    • Tacere Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Tacere Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Tacere Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Tacere Therapeutics, Inc. - Recent Pipeline Updates
  • Tacere Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Tacere Therapeutics, Inc., Key Information
  • Tacere Therapeutics, Inc., Key Facts
  • Tacere Therapeutics, Inc. - Pipeline by Indication, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Stage of Development, 2014
  • Tacere Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014
  • Tacere Therapeutics, Inc. - Phase I, 2014
  • Tacere Therapeutics, Inc. - Preclinical, 2014
  • Tacere Therapeutics, Inc. - Discovery, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Target, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Route of Administration, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Molecule Type, 2014
  • Tacere Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014
  • Tacere Therapeutics, Inc. - Recent Pipeline Updates, 2014

List of Figures

  • Tacere Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Stage of Development, 2014
  • Tacere Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014
  • Tacere Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014
  • Tacere Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top